Associated Papers
Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction.
Clemente-Moragón A et al.
Nature Communications, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.
Shorbaji A et al.
Npj Genomic Medicine, 2025
Altered O-glycosylation of β1-adrenergic receptor N-terminal single-nucleotide variants modulates receptor processing and functional activity.
Tuhkanen HE et al.
The Febs Journal, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Villa M et al.
British Journal of Cancer, 2024
Genetic Variation in ABCB1, ADRB1, CYP3A4, CYP3A5, NEDD4L and NR3C2 Confers Differential Susceptibility to Resistant Hypertension among South Africans.
Katsukunya JN et al.
Journal of Personalized Medicine, 2024
Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy.
Raimoglou D et al.
Anatolian Journal of Cardiology, 2024
rs1801253 Gly/Gly carriage in the ADRB1 gene leads to unbalanced cardiac sympathetic modulation as assessed by spectral analysis of heart rate variability.
Grossini E et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society, 2024
Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with non‑ischemic heart failure.
Telles TM et al.
Experimental and Therapeutic Medicine, 2024
PTPRD gene variant rs10739150: A potential game-changer in hypertension diagnosis.
Al-Eitan L
Plos One, 2024
Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.
Castaño-Amores C et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2023
β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome.
Fayed MS et al.
Future Science Oa, 2023
Associations between Selected ADRB1 and CYP2D6 Gene Polymorphisms in Children with Ventricular and Supraventricular Arrhythmias.
Moric-Janiszewska E et al.
Medicina (kaunas, Lithuania), 2023
Functional mutation, splice, distribution, and divergence analysis of impactful genes associated with heart failure and other cardiovascular diseases.
Mhatre I et al.
Scientific Reports, 2023
Impact of Neuroeffector Adrenergic Receptor Polymorphisms on Incident Ventricular Fibrillation During Acute Myocardial Ischemia.
Chevalier P et al.
Journal of the American Heart Association, 2023
Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.
Valentine H et al.
Cancer Research Communications, 2022
Pharmacogenetics may explain part of the interindividual variability of dobutamine pharmacodynamics in neonates.
Hallik M et al.
British Journal of Clinical Pharmacology, 2022
Genetic biomarkers of life-threatening pheochromocytoma-induced cardiomyopathy.
Amar J et al.
Endocrine-related Cancer, 2022
β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
Dumeny L et al.
Clinical and Translational Science, 2022
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers.
Guerra LA et al.
The Pharmacogenomics Journal, 2022
Lack of Effects of Renin-Angiotensin-Aldosterone System Activity and Beta-Adrenoceptor Pathway Polymorphisms on the Response to Bisoprolol in Hypertension.
Zeng W et al.
Frontiers in Cardiovascular Medicine, 2022
Beta-adrenergic receptors gene polymorphisms are associated with cardiac contractility and blood pressure variability.
Matuskova L et al.
Physiological Research, 2021
Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2021
Towards Understanding the Genetic Nature of Vasovagal Syncope.
Matveeva N et al.
International Journal of Molecular Sciences, 2021
Ligand-specific pharmacogenetic effects of nonsynonymous mutations.
Morningstar-Kywi N et al.
Pharmacogenetics and Genomics, 2021
Glycosylation-dependent cleavage of the human β1-adrenoceptor.
Ahles A et al.
Journal of Molecular and Cellular Cardiology, 2021
Association of Genetic Variances in ADRB1 and PPARGC1a with Two-Kilometre Running Time-Trial Performance in Australian Football League Players: A Preliminary Study.
Jacob Y et al.
Sports (basel, Switzerland), 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype.
Fonseca DJ et al.
Pharmacogenomics and Personalized Medicine, 2021
Genetic Variants behind Cardiovascular Diseases and Dementia.
Ho WM et al.
Genes, 2020
Pharmacogenetic factors affecting β-blocker metabolism and response.
Thomas CD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2020
Pharmacogenomics of Hypertension Treatment.
Rysz J et al.
International Journal of Molecular Sciences, 2020
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.
Van Driest SL et al.
The Journal of Pediatrics, 2020
The role of Beta-1 receptor gene polymorphism in Beta-Blocker therapy for vasovagal syncope.
Atici A et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2020
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Cacabelos R
International Journal of Molecular Sciences, 2020
The Impact of Pharmacogenomics in Personalized Medicine.
Singh DB
Advances in Biochemical Engineering/biotechnology, 2020
β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.
Shahin MH et al.
Journal of Clinical Pharmacology, 2019
Examination of the associations between m6A-associated single-nucleotide polymorphisms and blood pressure.
Mo XB et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension, 2019
[POLYMORPHISM OF THE BETA1- AND BETA2-ADRENORECEPTOR GENES AND BISOPROLOL EFFICIENCY IN PATIENTS WITH HEART FAILURE].
Pyvovar S et al.
Georgian Medical News, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
β1-Adrenoreceptor Polymorphisms and Blood Pressure: 49S Variant Increases Plasma Renin But Not Blood Pressure in Hypertensive Patients.
Sandilands AJ et al.
American Journal of Hypertension, 2019
β2-Adrenergic Receptor Gene Polymorphisms Are Associated with Cardiovascular Events But not All-Cause Mortality in Coronary Artery Disease Patients: A Meta-Analysis of Prospective Studies.
Li Y et al.
Genetic Testing and Molecular Biomarkers, 2019
Host genetic variants in sepsis risk: a field synopsis and meta-analysis.
Lu H et al.
Critical Care (london, England), 2019